APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Ascentage Pharma Group Inc.
Study ID
NCT03537482
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • APG-2575 — DRUG
    APG-2575 will be administered as an oral tablet

Study Details

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Key Dates

Start date
Aug 7, 2018
Status verified
Aug 2024
Primary completion
Sep 15, 2024
Completion
Feb 15, 2025

Study Design

Enrollment
90 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: single-agent, open-label, Phase I study of APG-2575
    The study consists of the dose escalation stage and the dose expansion stage

Primary Outcome Measure

Maximum Tolerated Dose (MTD) [ Time Frame: 28 days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Mayo ClinicJacksonvilleFlorida32224
Sikander Ailawadhi, MD
[email protected]
904-953-0853
sikander ailawdhi, md (PRINCIPAL_INVESTIGATOR)
Duke UnviersityDurhamNorth Carolina27701-
MDACCHoustonTexas77030
Tapan Kadia, MD
[email protected]
713-792-7734
Tapan Kadia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Jacksonville, FL

By research site
Mayo Clinic· Jacksonville, FLDuke Unviersity· Durham, NCMDACC· Houston, TX

Related Studies